JBIO
HEALTHCAREJade Biosciences Inc
$25.13-0.13 (-0.51%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving JBIO Today?
No stock-specific AI insight has been generated for JBIO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.57$28.00
$25.13
Fundamentals
Market Cap$1.2B
P/E Ratio—
EPS$-3.19
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume638K
Avg Volume (10D)—
Shares Outstanding49.4M
JBIO News
20 articles- Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 7, 2026
- Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 23, 2026
- Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical OfficerYahoo Finance·Apr 22, 2026
- Companies Like Jade Biosciences (NASDAQ:JBIO) Are In A Position To Invest In GrowthYahoo Finance·Mar 28, 2026
- Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 6, 2026
- Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout NearsMarketbeat·Feb 28, 2026
- Jade Biosciences to Participate in Upcoming ConferencesYahoo Finance·Feb 11, 2026
- H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak RevenueYahoo Finance·Jan 19, 2026
- Institutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last weekYahoo Finance·Jan 6, 2026
- Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 5, 2026
- Jade Biosciences Announces $45 Million Private PlacementYahoo Finance·Dec 15, 2025
- Jade Biosciences (JBIO): Analyst Lauds Entry into MarketYahoo Finance·Dec 10, 2025
- Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect?Yahoo Finance·Dec 4, 2025
- What Makes Jade Biosciences, Inc. (JBIO) a New Buy StockYahoo Finance·Nov 18, 2025
- Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. (JBIO): Here's What You Should KnowYahoo Finance·Nov 18, 2025
- Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 13, 2025
- Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025Yahoo Finance·Nov 8, 2025
- Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025Yahoo Finance·Oct 17, 2025
- Jade Biosciences Raises $135 Million Through Private PlacementYahoo Finance·Oct 7, 2025
- Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune DiseasesYahoo Finance·Oct 7, 2025
All 20 articles loaded
Price Data
Open$25.51
Previous Close$25.26
Day High$26.14
Day Low$24.67
52 Week High$28.00
52 Week Low$6.57
52-Week Range
$6.57$28.00
$25.13
Fundamentals
Market Cap$1.2B
P/E Ratio—
EPS$-3.19
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume638K
Avg Volume (10D)—
Shares Outstanding49.4M
About Jade Biosciences Inc
Jade Biosciences, Inc. is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—